touchCONGRESS Higher-risk MDS and newly diagnosed AML: What are the latest developments from EHA 2022?
Watch this two-part activity exploring recent developments in the treatment of higher-risk MDS and newly diagnosed AML. Filmed following the EHA 2022 Hybrid Congress.
Introduction
Emerging therapeutic strategies for patients with HR-MDS
Emerging treatments for patients with newly diagnosed AML who are unfit for intensive chemotherapy
Advances in risk assessment and treatment personalization for patients with HR-MDS or AML
Overview
Watch Dr Esther Oliva summarize and share her interpretation of the latest data from the EHA 2022 Hybrid Congress on emerging treatments for higher-risk MDS and newly diagnosed AML. During the presentation she considers:
- Emerging therapeutic strategies for patients with HR-MDS
- Emerging treatments for patients with newly diagnosed AML who are unfit for intensive chemotherapy
- Advances in risk assessment and treatment personalization for patients with HR-MDS or AML
Dr Esther Oliva is Associate Professor of Blood Diseases, Oncology and Rheumatology, and leads the MDS, aplastic anaemia and anaemia section of the Hematology Unit at the Grande Ospedale Metropolitano in Reggio Calabria, Italy. read more
Dr Oliva developed a unique instrument for the evaluation of quality of life (QOL) in patients with MDS (QOL-E), and the Haematological Malignancy Patient-Reported Outcome Measure (HM-PRO). Additionally, she has developed and coordinated clinical trials in pharmacology and QOL research.
Dr Oliva is a junior editor of the American Journal of Blood Research and associate editor of Frontiers in Oncology – Hematological Malignancies. She was the former chair and is now the co-chair of the European Hematology Association (EHA) Scientific Working Group ‘Quality of Life and Symptoms’. She is a founding member and vice president of the QOL-ONE research association. Dr Oliva is also an active member of the EHA, the American Society of Hematology, the International Society of Quality of Life, and the Italian Society of Hematology.
Dr Esther Oliva discloses: Advisory board or panel fees from AbbVie, Alexion, Amgen, Celgene, IQVIA and Novartis. Consultancy fees from Celgene, Janssen and Novartis.
Prof. Michael Heuser considers the latest data from the EHA 2022 Hybrid Congress on new and emerging treatments for the improvement of outcomes in patients with higher-risk MDS and newly diagnosed AML.
In this interview, Prof. Michael Heuser answers the following questions:
- Based on data presented at EHA 2022, which emerging treatments are most likely to impact future clinical practice for patients with HR-MDS?
- What do the latest data presented at EHA 2022 tell us about the clinical relevance of TP53 mutation in HR-MDS and newly diagnosed AML?
- To what extent will lower-intensity treatment regimens improve patient outcomes in newly diagnosed AML ineligible for intensive chemotherapy? Which of the emerging regimens do you think will be most important?
- Based on the latest research presented at EHA 2022, which prognostic tools and biomarkers do you consider most promising to support treatment decisions in HR-MDS or newly diagnosed AML?
Prof. Michael Heuser holds a Chair for Molecular Therapies in Hematology at Hannover Medical School in Hannover, Germany. read more
He is a senior attending physician in the Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, and executive board member of the Comprehensive Cancer Center Niedersachsen.
His research focuses on the pathogenesis of MDS and AML, and on measurable residual disease by next-generation sequencing. Prof. Heuser has been a clinical investigator in 70 clinical trials and has published more than 200 peer-reviewed publications.
Prof. Michael Heuser discloses: Honoraria from AbbVie, Eurocept, Janssen, Jazz Pharmaceuticals, Novartis and Takeda. Consultancy fees from AbbVie, Agios, BMS, Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Novartis, Pfizer, PinotBio, Roche and Tolremo. Research funding (for institution) from AbbVie, Agios, Astellas, Bayer Pharma AG, BergenBio, Daiichi Sankyo, Jazz Pharmaceuticals, Loxo Oncology, Novartis, Pfizer and Roche.
Dr Yishai Ofran considers the latest data from the EHA 2022 Hybrid Congress on new and emerging treatments for the improvement of outcomes in patients with higher-risk MDS and newly diagnosed AML.
In this interview, Dr Yishai Ofran answers the following questions:
- Based on data presented at EHA 2022, which emerging treatments are most likely to impact future clinical practice for patients with HR-MDS?
- What do the latest data presented at EHA 2022 tell us about the clinical relevance of TP53 mutation in HR-MDS and newly diagnosed AML?
- To what extent will lower-intensity treatment regimens improve patient outcomes in newly diagnosed AML ineligible for intensive chemotherapy? Which of the emerging regimens do you think will be most important?
- Based on the latest research presented at EHA 2022, which prognostic tools and biomarkers do you consider most promising to support treatment decisions in HR-MDS or newly diagnosed AML?
Dr Yishai Ofran is the Director of the Department of Hematology at Jerusalem’s Shaare Zedek Medical. A highly accomplished researcher and clinician, he also serves as the chair of the Israeli Leukemia Group. read more
Between 2009 and 2020, Dr Ofran was a senior physician and director of the leukaemia service at Ramban Hospital in Israel, and served as the Senior Lecturer and the Head of the Hematology Department at the Faculty of Medicine at the Technion, Israel. He has been responsible for designing and implementing numerous treatment protocols with a focus on providing individualized treatment approaches for every patient, based on the patient’s specific medical and genetic makeup.
He is a member of several prominent international medical forums, including a selected group of experts who wrote leukaemia treatment guidelines for the European Society for Medical Oncology (ESMO) and the leukaemia core committee of the US-based Eastern Cooperative Oncology Group (ECOG). As an active member of the European LeukemiaNet (ELN), he is a member of the group who writes European recommendations for advanced molecular monitoring of patients with leukaemia, and has directly contributed to the advancement of haematological care in hospitals across the globe.
He has written or contributed to over 80 journal articles and sits on multiple editorial boards for prominent periodicals.
Dr Yishai Ofran discloses: Speaker bureau fees from AbbVie, Astellas, Medison and Neopharm.
Dr Esther Oliva considers the latest data from the EHA 2022 Hybrid Congress on new and emerging treatments for the improvement of outcomes in patients with higher-risk MDS and newly diagnosed AML.
In this interview, Dr Esther Oliva answers the following questions:
- Based on data presented at EHA 2022, which emerging treatments are most likely to impact future clinical practice for patients with HR-MDS?
- What do the latest data presented at EHA 2022 tell us about the clinical relevance of TP53 mutation in HR-MDS and newly diagnosed AML?
- To what extent will lower-intensity treatment regimens improve patient outcomes in newly diagnosed AML ineligible for intensive chemotherapy? Which of the emerging regimens do you think will be most important?
- Based on the latest research presented at EHA 2022, which prognostic tools and biomarkers do you consider most promising to support treatment decisions in HR-MDS or newly diagnosed AML?
Dr Esther Oliva is Associate Professor of Blood Diseases, Oncology and Rheumatology, and leads the MDS, aplastic anaemia and anaemia section of the Hematology Unit at the Grande Ospedale Metropolitano in Reggio Calabria, Italy. read more
Dr Oliva developed a unique instrument for the evaluation of quality of life (QOL) in patients with MDS (QOL-E), and the Haematological Malignancy Patient-Reported Outcome Measure (HM-PRO). Additionally, she has developed and coordinated clinical trials in pharmacology and QOL research.
Dr Oliva is a junior editor of the American Journal of Blood Research and associate editor of Frontiers in Oncology – Hematological Malignancies. She was the former chair and is now the co-chair of the European Hematology Association (EHA) Scientific Working Group ‘Quality of Life and Symptoms’. She is a founding member and vice president of the QOL-ONE research association. Dr Oliva is also an active member of the EHA, the American Society of Hematology, the International Society of Quality of Life, and the Italian Society of Hematology.
Dr Esther Oliva discloses: Advisory board fees from AbbVie, Alexion, Amgen, Celgene, IQVIA and Novartis. Consultancy fees from Celgene, Janssen and Novartis.
Please Select A Video:
Learning Objectives & Overview
Overview
Stay up to date with the latest data on new and emerging treatments to improve outcomes for patients with higher-risk myelodysplastic syndromes (HR-MDS) and newly diagnosed acute myeloid leukaemia (AML) in this two-part activity. This activity was filmed following the EHA 2022 Hybrid Congress.
Learning Objectives
After watching this activity, participants should be better able to:
- Summarize the data for emerging therapeutic strategies for patients with HR-MDS
- Recall the data for emerging treatments for patients with newly diagnosed AML who are unfit for intensive chemotherapy
- Discuss advances in risk assessment and treatment personalization for patients with HR-MDS or AML
Register to touchONCOLOGY for FREE
- Peer-reviewed journals and expert opinions
- Interactive CME and e-learning modules
- Video conference highlights
